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Vitamin D deficiency 
Secondary osteoporosis 
a b s t r a c t 
Gaucher disease (GD) is the most prevalent lysosomal storage disorder. Bone marrow infiltration by Gaucher 
cells and the subsequent inflammatory events cause bone lesions, which frequently accompany anemia, throm- 
bocytopenia, and hepatosplenomegaly. We present the case of a 22-year old woman with GD who was referred 
for bone assessment after 5 years on enzyme replacement therapy (ERT). Although the patient’s hematological 
parameters improved with ERT showing good response to treatment, she had extensive bone marrow infiltra- 
tion, and very low bone density. In addition, the patient reported severe bone pain, weakness, and difficulties 
walking up the stairs. Bone and mineral metabolism assessment showed hypocalcemia, hypophosphatemia, ele- 
vated bone alkaline phosphatase, secondary hyperparathyroidism and vitamin D deficiency. All these parameters 
were compatible with nutritional osteomalacia, and they improved with vitamin D and calcium supplementation. 
Worsening of her anemia and sustained vitamin D deficiency led to the diagnosis of celiac disease. We highlight 
the importance of detecting co-morbidities in patients with GD, especially in cases showing poor or inadequate 












































Gaucher disease (GD) is the most prevalent lysosomal storage dis-
rder with a pan-ethnic distribution and an incidence of approximately
/40,000 to 1/60,000 births, respectively, rising to 1/800 in Ashkenazi
ews ( Stirnemann et al., 2017 ). Gaucher disease is an autosomal re-
essive, inherited disease caused by pathogenic variants in GBA1 that
eads to deficiency of glucocerebrosidase (GCase), the enzyme that cat-
lyzes the hydrolysis of the glycolipid glucosylceramide (GlcCer) to ce-
amide and glucose ( Stirnemann et al., 2017 ). Deficiency of GCase activ-
ty results in GlcCer accumulation in macrophages, mainly in the spleen,
iver, bone marrow, and lungs ( Stirnemann et al., 2017 ; Futerman et al.,
004 ). 
Bone marrow infiltration by Gaucher cells and the subsequent in-
ammatory events cause bone lesions, which frequently accompany
nemia, thrombocytopenia, and hepatosplenomegaly. Patients with GD
ay present with bone pain, osteoporosis, fragility fractures, bone in-
arcts, and avascular necrosis ( Marcucci et al., 2014 ). Even hemato-
ogically asymptomatic patients may present with bone complications
hat affect their quality of life . The pathogenesis of such complications,
evertheless, remains to be elucidated ( Mikosch and Hughes, 2010 ).∗ Corresponding author. 
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ayed puberty. 
Enzyme replacement therapy (ERT) rapidly improves hematological
arameters, whereas bone lesions respond more slowly, and complete
ecovery remains uncertain ( De Fost et al., 2008 ; Deegan et al., 2011 ).
e report the case of an adult patient with GD on ERT who had bone
anifestations that were initially attributed to GD but were found to be
ompounded by osteomalacia secondary to asymptomatic celiac disease
CD). 
ase report 
A 22-year old female with GD was referred for assessment of GD-
elated bone involvement after 5 years on Velaglucerase therapy. The
atient reported severe bone pain, weakness, and difficulties walk-
ng up the stairs that led to functional decline. Her body weight,
eight and BMI were 41 kg, 146 cm, and 19.2 kg/m 2 , respectively.
t 17 years old, she was investigated for severe hepatosplenomegaly
spleen length = 18 cm, liver length = 17 cm), and pancytopenia (hema-
ocrit: 15%, hemoglobin: 5.3 g%, white blood cell count: 1.750/mm 3 ,
latelet count: 160,000/mm 3 ). Bone marrow evaluation showed diffuseil 2020 
rticle under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Fig. 1. Radiograph of the spine showing bicon- 
cave deformities in lumbar vertebrae (A) and 
radiograph of lower limb showing ill-defined 
radiolucent areas in both proximal femurs and 



















































































i  nfiltration of giant foamy cells with eccentric nuclei, compatible with
aucher cells. Diagnosis of GD type 1 was confirmed by enzymatic ac-
ivity assay (GCase activity = 1.3 nmoles/h/mg prot; reference value:
.14–24.8) and GBA1 genetic testing (c.1226A > G/c.1448T > C). Levels
f chitotriosidase, a marker of GD activity, were high (2.488 𝜇mol/l.h;
eference range = 7.77 a 110.50 𝜇mol/l.h). The patient’s eldest sister
as confirmed to have asymptomatic GD. 
Six months after diagnosis, treatment with 60 U/kg of intravenous
elaglucerase every two weeks was initiated. After two years of treat-
ent, the patient showed very low spine bone mineral density values
0.767 g/cm 2 ; Z-score = − 4.0). She was therefore started on intravenous
nfusions of 90 mg of pamidronate every 60 days for 6 months, and
n calcium and vitamin D supplementation . The latter was prescribed
ven though her vitamin D levels had never been tested. The patient
ad her menarche at the age of 19 years with regular menses lasting
pproximately 7 days. Long menses were initially considered the cause
f her persistent anemia, which was treated with iron infusions due to
ntolerance to oral iron supplements. 
Her imaging assessments revealed several abnormalities. Spine X-
ays showed biconcave deformities in the lumbar vertebrae, especially
3 and L4. Lower limb X-rays showed ill-defined radiolucent areas in
oth proximal femurs, and Erlenmeyer flask deformity of the distal fe-
urs ( Fig. 1 A and B). Hand and wrist radiographs showed a bone age
f 14.5 years (Greulich and Pyle standard ( Greulich and Pyle, 1959 )),
hereas chronological age was 22 years. Magnetic resonance imaging
howed bone marrow infiltration in the spine, femurs, iliac bones, tib-
ae, humerus, radius, ulnae, astragalus and calcaneus, and bone edema
n the humerus, radius, and calcaneus . Moreover, there was enlargement
f the liver and a moderate increase in spleen volume (1.3 and 7.3 times
arger than the normal reference values, respectively). 
Bone mineral density assessment revealed spine, total femur, and
otal skeleton Z-scores of − 4.2, − 3.0, and − 3.2, respectively, indicating
hat the patient had very low BMD. Although there are no reference
alues for individuals aged less than 40 years to date, TBS was also
etermined. Absolute BMD (g/cm 2 ), Z-scores and TBS values are shown
n Table 1 . 
Laboratory tests while on ERT showed low hemoglobin and
ematocrit (11.4 g/dL 37 % respectively) , normal platelet counts
199,000/mm 3 ), and an acceptable chitotriosidase level (177umol/hl).
ssessment of bone and mineral metabolism showed hypocalcemia, hy-
ophosphatemia, elevated bone-specific alkaline phosphatase, CTX, andTH levels, and vitamin D deficiency ( Table 2 ). Her GD was in metabolic
ontrol due to ERT ( Drelichman et al., 2015 ). Therefore, her bone symp-
oms were attributed to osteomalacia secondary to vitamin D deficiency.
alcium supplementation and administration of high doses of vitamin
 were prescribed. 
At the 1-year follow-up visit, the patient was 23 years old. She
howed no changes in body weight or stature, and reported a significant
mprovement in pain and mobility. She had received 100,000 IU of vita-
in D 3 every 15 days for 3 months, and a non-specified daily oral dose of
alcium. Chitotriosidase levels and platelet counts were within normal
anges, showing that GD remained stable and that the patient was re-
ponding well to Velaglucerase. In contrast, anemia had worsened, and
he vitamin D deficiency persisted. Although calcemia, phosphatemia,
AP, and CTX values had improved, they still remained outside the nor-
al range ( Table 2 ). Despite the absence of gastrointestinal symptoms, a
alabsorptive disease in addition to GD was suspected. Serological tests
ere positive for celiac disease (CD): antitransglutaminase IgA antibody
evels were 166 U (reference value < 10 U), and anti-deaminated gliadin
eptide IgG antibody levels were 101 U (reference value < 20 U). Up-
er digestive endoscopy showed villous atrophy in the bulb and second
art of the duodenum, and intestinal mucosa biopsy revealed the pres-
nce of lymphocytic enteritis type 3c according to Marsh’s classification .
oth findings were compatible with CD. No Gaucher cells were detected.
he timeline of events is shown in Fig. 2 . The patient was prescribed a
luten-free diet (GFD), and she was instructed to continue taking daily
alcium supplementation and monthly supplementation with 100,000
U of vitamin D 3. 
At the 2-year follow-up visit, the patient reported she was not com-
lying with the GFD and only partially complying with calcium and
itamin D supplementation due to socioeconomic and environmental
imitations. Clinical course was nevertheless favorable. 
Three years after the first bone assessment (3-year follow-up visit),
he patient showed no significant changes in MRI, or in spine and fe-
ur X-rays. Bone age was 18 years (the highest value referenced in the
reulich and Pyle atlas). A substantial increase in spine, hip, and to-
al skeleton BMD values was observed, and all three sites were within
ge-matched reference ranges . A significant increase in TBS was also
bserved ( Table 1 ). All the biochemical parameters of bone and mineral
etabolism had improved, and serum calcium, phosphorus and PTH
alues were within the normal range. Although a three -fold increase
n 25OHD was observed as compared to initial values, levels remained
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Table 1 
Bone densitometry and TBS at baseline and throughout the 3-year follow-up. 
Age (years) Spine L1-L4 g/cm 2 Z-score 1 TBS Total Femur g/cm 2 Z-score Total Skeleton g/cm 2 Z-score 
22 0.589 − 4.1 1120 0.556 − 3.0 0.647 − 3.2 
23 0.820 + 23% ∗ − 2.2 0.808 + 25% ∗ − 1.0 0.793 + 14.6 ∗ − 1.8 
24 1.119 + 30% ∗ − 0.2 1374 + 22.6% ∗ 1.075 + 27 % ∗ 1.0 0.950 + 15.7 % ∗ − 0.3 
25 1.284 + 14.7% ∗ + 1.6 1.214 + 13 % ∗ + 2.2 1.106 + 16. % ∗ + 1.2 
∗ Increase % vs. previous value 
1 Z ‐score is defined as the number of standard deviations from the mean BMD of a healthy population of the same age, race, and sex. According 
to the International Society for Clinical Densitometry guidelines, Z-scores are used in patients under the age of 50 years and a value below ‐2 
indicates reduced BMD [Position Development Conference on bone densitometry. J Clin Densitom. 2013;16(4):455–66]. 
Table 2 
Bone and mineral metabolism at baseline and throughout the 3-year follow-up. 
Age (years) 
Serum determinations Reference range 22 # 23 ∗ 24 ∗ 25 ∗ 
Calcium 8.4–10.2 mg/dl 7.4 8.3 8.7 ∗∗ 8.9 ∗∗ 
Phosphate 2.7–4.5 mg/dl 2.9 2.2 3.2 ∗∗ 3.3 ∗∗ 
Bone Alkaline Phosphatase 31–95 U/l 1815 653 234 109 
25-OH-D ≥ 20 ng/ml 6.7 8.1 15.8 19 
Parathormone 15.0–65.0 pg/ml 431 227 84 56 ∗∗ 
CrossLaps Premenopause: 0.3–0.58 ng/ml 4.23 1.88 2.59 1.36 
# After 5 years on enzyme replacement therapy (ERT) 
∗ Receiving ERT, and vitamin D and calcium supplementation 
∗∗ Normalized values 
Fig. 2. Timeline of clinical events recorded 
from initial diagnosis of Gaucher disease to di- 
agnosis of celiac disease. 
The upper lines show age at initiation and du- 
ration of each treatment. 
(y): years; BMD: bone mineral density; 






































2  n the deficiency range ( Table 2 ). The patient informed us that she had
ever followed the GFD. 
iscussion 
Gaucher disease is in the constellation of rare diseases . It is char-
cterized by marked phenotypic heterogeneity and a variable clinical
ourse. The disease can present with varying degrees of severity at all
tages of life. 
The classic clinical triad is thrombocytopenia, anemia, and
isceromegaly (mainly splenomegaly). Nevertheless, around 35% of pa-
ients initially have bone symptoms (pain, fractures, osteoporosis, avas-
ular necrosis) as the only presenting symptom or together with hema-
ological manifestations ( Rossi et al., 2011 , Ben- Chetrit et al., 2011 ). 
GD patients can suffer bone complications that severely affect their
uality of life. Bone assessment at the time of diagnosis is therefore
mportant so as to determine the degree of bone involvement. Although
RT does not totally prevent the onset of bone lesions, it has been
roven to effectively decrease bone pain and bone crises, and to
ecrease the frequency of new bone events. It has also been shown tomprove bone mineral density and to decrease infiltration by Gaucher
ells ( Drelichman et al., 2016 ). 
At the time of the first bone assessment performed by our team,
he patient had been receiving Velaglucerase for almost 5 years . Thera-
eutic goals for anemia, thrombocytopenia, and hepatosplenomegaly,
nd almost normal levels of chitotriosidase were achieved, showing
ood hematological response to treatment ( Drelichman et al., 2015 ).
lthough vitamin D deficiency has been reported in GD ( Mikosch et al.,
008 ; Parisi et al., 2008 ), the deficit observed in our patient was se-
ere, and her response to treatment with high doses of vitamin D was
low and insufficient. Further tests were therefore conducted in order
o detect the cause of poor response to vitamin D supplementation, and
iagnosis of malabsorption secondary to celiac disease was established.
Positive autoantibodies have been observed more frequently in
D type 1 than in the healthy population (52% vs. 26%), though the
revalence of clinically active autoimmune diseases is not higher in
D1 ( Serratrice et al., 2018 ). The presence of autoantibodies has also
een reported in other lysosomal storage disorders ( Dimitriou et al.,
019 ). Celiac disease could therefore be considered a comorbidity





























































































































B  r a concurrent disease associated with GD, since it is a chronic
mmune-mediated disease of the small intestine that is precipitated
n genetically predisposed subjects by ingestion of gluten ( Ludvigsson
t al., 2013 ) . To our knowledge, however, no significant association
etween GD and CD has been reported to date. 
Unlike GD, the prevalence of CD is high, affecting approximately 1%
f the population worldwide ( Dubé et al., 2005 ; Fasano et al., 2003 ).
eliac disease may also present with anemia, weakness, abdominal dis-
omfort, growth retardation, developmental delay, osteopenia, osteo-
orosis, and increased fracture risk. The pathogenesis of bone compli-
ations involves two main mechanisms: intestinal malabsorption of cal-
ium and vitamin D, and the presence of chronic inflammation ( Bianchi
nd y Bardella, 2008 ). Although osteopenia and osteoporosis are fre-
uent in symptomatic celiac patients, they may also occur without the
ypical gastrointestinal symptoms of diarrhea and abdominal distension
 González et al., 1995 ; Mazure et al., 1994 ; Shaker et al., 1997 ). 
The patient reported here presented with bone pain, weakness, low
one mass, and a history of growth retardation and delayed puberty. All
hese clinical signs are common to both GD and CD. Nevertheless, the
bserved visceromegaly and pancytopenia initially led to diagnosis of
D. Although the patient showed good hematological and visceral re-
ponse to ERT, she was started on short-term bisphosphonate treatment
ue to her very low spine BMD . Given the lack of assessment of the
atient’s vitamin D status, administration of bisphosphonate treatment
ay have been inadequate due to its hypocalcemic effect. 
The biochemical study of bone and mineral metabolism evidenced
itamin D deficiency, hypocalcemia, secondary hyperparathyroidism,
nd highly elevated BAP levels, all of which are biochemical features of
n osteomalacic syndrome. 
Osteomalacia is a metabolic bone disorder affecting skeletal mineral-
zation. It is infrequent in symptomatic CD, and even more infrequent as
n extra intestinal clinical form of presentation of CD ( Gifre et al., 2011 ).
on pathognomonic clinical, radiographic, and biochemical features in-
lude crippling pain, muscle weakness mainly of the proximal muscles,
nd radiological finding of pseudofractures or Looser’s zones.The lat-
er were not detected on our patient’s radiographs . Of note, perform-
ng bone scintigraphy might have allowed identifying focal areas of in-
reased uptake due to the presence of Looser´s zones, since these sites
an often be visualized on radionuclide images before they become ra-
iographically apparent. 
Diagnosis of osteomalacia may require bone biopsy demonstrating
ccumulation of non-mineralized or poorly mineralized osteoid tissue.
owever, complementary to clinical findings, the presence of hypocal-
emia, hypophosphatemia, severe vitamin D deficiency, secondary hy-
erparathyroidism, and markedly elevated BAP levels allows establish-
ng diagnosis of osteomalacia with no need for confirmation by invasive
ethods ( Bingham and Fitzpatrick, 1993 ). 
The patient presented here had very high bone formation and re-
orption marker levels (BAP and CTX). There is considerable variabil-
ty in reported levels of bone remodeling markers in GD. Van Dussen
ound that most patients had low osteocalcin levels and CTX levels in
he normal range. The authors therefore posited an imbalance in bone
emodeling at the expense of a decrease in bone formation ( van Dussen
t al., 2011 ). Conversely, BAP is markedly increased in osteomalacia, in
hich mineralization is impaired ( Harris et al., 1969 ). 
The cause of osteomalacia secondary to vitamin D deficiency is mul-
ifactorial in the patient presented here, namely insufficient exposure
o sunlight and malabsorption of vitamin D and calcium. The resulting
ypocalcemia promoted a secondary increase in PTH. The secondary
yperparathyroidism, in turn, promoted conversion of 25OHD to the
ctive metabolite 1,25(OH) 2 D, decreasing the half-life of 25OHD and
xacerbating the Vitamin D deficiency ( Mawer, 1997 ). 
Normalization of biochemical parameters is expected with a GFD.
espite the patient not complying with the GFD, her blood calcium lev-
ls normalized and her PTH and BAP levels decreased, likely due to
alcium and vitamin D supplementation. Although the patient’s vitamin levels remained in the deficiency range, the attained increase was
ufficient to induce positive biochemical changes. 
Even though the patient’s estradiol levels were not assessed, sponta-
eous menarche and resumption of menses would seem to confirm that
er estradiol levels were adequate. Nevertheless, neither the observed
ormonal recovery nor the almost five years on Velaglucerase treatment
mproved bone mass. BMD may be decreased in untreated GD patients,
nd ERT improves and may even normalize BMD in children and adoles-
ents. Lumbar spine DXA Z-scores have been reported to improve from
 1.95 (95% CI − 2.26 to − 1.64) to − 0.67 (95% CI − 1.09 to − 0.26) in
oung adults on ERT ( Mistry et al., 2011 ). 
In the case reported here, the very low BMD values observed prior
o treatment indicate the replacement of mineralized by unmineralized
steoid, which is characteristic of osteomalacia. Supplementation with
alcium and vitamin D reinitiated mineralization of the accumulated os-
eoid, resulting in a remarkable increase in BMD. Lumbar spine Z-score
mproved from − 4.0 to + 1.6, and absolute BMD increased 68 %, 65
, and 46%, at the lumbar spine, total femur, and total skeleton re-
pectively, reaching normal values at all three skeletal sites. Changes
f such magnitude are consistent with reported findings on response to
steomalacia treatment and are in contrast to that observed in treated
steoporotic patients, even in those receiving osteoanabolic drugs such
s teriparatide ( Bhambri et al., 2006 ) . The marked increase in BMD ob-
erved in our patient not only indicates adequate response to treatment
ut also confirms diagnosis of osteomalacia ( Bhambri et al., 2006 ) 
Trabecular bone score is an index of bone microarchitecture. It is
btained using special software that is installed in the same equipment
sed for DXA densitometry of the lumbar spine. Values below 1200 indi-
ate degraded bone structure ( Harvey et al., 2015 ). Our patient showed
 remarkable change in TBS, which shifted from very low (1120) prior
o calcium and vitamin D supplementation to normal values at two years
ollow up. There are reports of altered TBS values in GD patients ( Baldini
t al., 2018 , Oliveri et al., 2019 ). To our knowledge, there are no data
n longitudinal follow up of TBS during ERT or in osteomalacia. 
Unlike response of CD-associated osteoporosis to a GFD, total recov-
ry of bone quantity (normalization of BMD) and quality (normalization
f TBS) was observed in the patient described here. 
To sum up, we highlight the importance of detecting co-morbidities
n patients with GD, especially in cases showing poor or inadequate re-
ponse to enzyme replacement or substrate inhibition therapy. In the
ase of the patient reported here, who showed bone involvement sec-
ndary to GD, complete assessment of bone and mineral metabolism
as key to finally identify an undiagnosed co-morbidity such as celiac
isease. 
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